Open Access
Med Sci (Paris)
Volume 34, Number 6-7, Juin–Juillet 2018
Les Cahiers de Myologie
Page(s) 540 - 546
Section M/S Revues
Published online 31 July 2018
  1. Hughes A, Yong ASM. Immune effector recovery in chronic myeloid leukemia and treatment-free remission. Front Immunol 2017 ; 8 : 1–12. [PubMed] [Google Scholar]
  2. Bower H, Björkholm M, Dickman PW, et al. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 2016 ; 34 : 2851–2858. [CrossRef] [PubMed] [Google Scholar]
  3. Rea D, Henry G, Khaznadar Z, Etienne G, et al. Natural killer cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia : the Immunostim study. Haematol 2017 ; 102 : 1368–1377. [CrossRef] [Google Scholar]
  4. Yilmaz M, Jabbour E. Treating early in the disease course: lessons from the CML model. Semin Oncol 2015 ; 42 : 876–886. [CrossRef] [PubMed] [Google Scholar]
  5. Rohon P, Porkka K, Mustjoki S. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur J Haematol 2010 ; 85 : 387–398. [CrossRef] [PubMed] [Google Scholar]
  6. Konjevic G, Vuletic A. Mirjacic Martinovic K. Natural killer cell receptors: alterations and therapeutic targeting in malignancies. Immunol Res 2015 ; 64 : 25–35. [Google Scholar]
  7. Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer 2016 ; 16 : 7–19. [CrossRef] [PubMed] [Google Scholar]
  8. Pahl J, Cerwenka A. Tricking the balance: NK cells in anti-cancer immunity. Immunobiology 2017 ; 222 : 11–20. [CrossRef] [PubMed] [Google Scholar]
  9. Chester C, Fritsch K, Kohrt HE. Natural killer cell immunomodulation: targeting activating, inhibitory, and co-stimulatory receptor signaling for cancer immunotherapy. Front Immunol 2015 ; 6 : 601. [CrossRef] [PubMed] [Google Scholar]
  10. Narendra BL, Reddy KE, Shantikumar S, Ramakrishna S. Immune system: a double-edged sword in cancer. Inflamm Res 2013 ; 62 : 823–834. [Google Scholar]
  11. Cheng M, Chen Y, Xiao W, et al. NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol 2013 ; 10 : 230–252. [CrossRef] [PubMed] [Google Scholar]
  12. Mellqvist UH, Hansson M, Brune M, et al. Natural killer cell dysfunction and apoptosis induced by chronic myelogenous leukemia cells: role of reactive oxygen species and regulation by histamine. Blood 2000 ; 96 : 1961–1968. [Google Scholar]
  13. Chen CI, Koschmieder S, Kesrtiens L, et al. NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice. Leukemia 2012 ; 26 : 465–474. [CrossRef] [PubMed] [Google Scholar]
  14. Hughes A, Clarson J, Tang C, et al. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. Blood 2017 ; 129 : 1166–1176. [Google Scholar]
  15. Boissel N, Rea D, Vannary T, Dulphy N. BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia. J Immunol 2006 ; 176 : 5108–5116. [CrossRef] [PubMed] [Google Scholar]
  16. Pierson BA, Miller JS. CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis. Blood 1996 ; 88 : 2279–2287. [Google Scholar]
  17. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of real-time quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia: a Europe against cancer program. Leukemia 2003 ; 17 : 2318–2387. [CrossRef] [PubMed] [Google Scholar]
  18. Chomel JC, Bonnet ML, Sorel N, et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood 2011 ; 118 : 3657–3660. [Google Scholar]
  19. Graham S, Jørgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002 ; 99 : 319–325. [Google Scholar]
  20. Chomel JC, Bonnet ML, Sorel N, et al. Evaluation of leukemic stem cell persistence in chronic myeloid leukemia (CML) patients in complete molecular remission induced by first line TKI therapies. Blood 2012 ; 120 : 3726. [Google Scholar]
  21. Etienne G, Guilhot J, Rea D, et al. Long-term follow-up of the french Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol 2017 ; 35 : 298–305. [CrossRef] [PubMed] [Google Scholar]
  22. Salih J, Hilpert J, Placke T, et al. The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity. Int J Cancer 2010 ; 127 : 2119–2128. [CrossRef] [PubMed] [Google Scholar]
  23. Rohon P. Biological therapy and the immune system in patients with chronic myeloid leukemia. Int J Hematol 2012 ; 96 : 1–9. [CrossRef] [PubMed] [Google Scholar]
  24. Chen CI, Maecker HT, Lee PP. Development and dynamics of robust T-cell responses to CML under imatinib treatment. Blood 2008; 111 : 5342–5349. [Google Scholar]
  25. Eissen DN, Michelo CM, Preijers FWMB, et al. Selective expansion of human natural killer cells leads to enhanced alloreactivity. Cell Mol Immunol 2014 ; 11 : 160–168. [CrossRef] [PubMed] [Google Scholar]
  26. Kreutzman A, Juvonen V, Kairisto V, et al. Mono-oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 2010 ; 116 : 772–782. [Google Scholar]
  27. Christiansson L, Söderlund S, Mangsbo S, et al. The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responses. Mol Cancer Ther 2015 ; 14 : 1181–1191. [Google Scholar]
  28. El Missiry M, Adnan AS, Al-Samadi A, et al. Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia. J Cancer Res Clin Oncol 2016 ; 142 : 1041–1050. [CrossRef] [PubMed] [Google Scholar]
  29. Mustjoki S, Auvinen K, Kreutzman A, et al. Rapid mobilization of cytotoxic lymphocytes induced by dasatinb therapy. Leukemia 2013 ; 27 : 914–924. [CrossRef] [PubMed] [Google Scholar]
  30. Qiu ZY, Xu W, Li JY. Large granular lymphocytosis during dasatinib therapy. Cancer Biol Ther 2014 ; 15 : 247–255. [CrossRef] [PubMed] [Google Scholar]
  31. Iriyama N, Fujisawa S, Yoshida C, et al. Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study. Am J Hematol 2015 ; 90 : 819–824. [CrossRef] [PubMed] [Google Scholar]
  32. Kim DH, Kamel-Reld S, Chang H, et al. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematol 2009 ; 94 : 135–139. [CrossRef] [Google Scholar]
  33. Hayashi Y, Nakamae H, Katayama T, et al. Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib. Leuk Lymphoma 2012 ; 53 : 1084–1089. [CrossRef] [PubMed] [Google Scholar]
  34. Mahon FX, Réa D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010 ; 11 : 1029–1035. [CrossRef] [PubMed] [Google Scholar]
  35. Ross DM, Brandford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013 ; 122 : 515–522. [Google Scholar]
  36. Imagawa J, Tanaka H, Okada M, et al. Discontinuation of dasatinib in patients with chronic myeloid leukemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicenter phase 2 trial. Lancet Haematol 2015 ; 2 : e528–e535. [CrossRef] [PubMed] [Google Scholar]
  37. Rea D, Nicolini FE, Tulliez M, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia : interim analysis of the STOP 2G-TKI study. Blood 2017 ; 129 : 846–854. [Google Scholar]
  38. Llander M, Olsson-Strömberg U, Schlums H, et al. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia 2017 ; 31 : 1108–1116. [CrossRef] [PubMed] [Google Scholar]
  39. Kimura S. Current status of ABL tyrosine kinase inhibitors stop studies for chronic myeloid leukemia. Stem Cell Investig 2016 ; 3 : 36. [CrossRef] [PubMed] [Google Scholar]
  40. Kumagai T, Nakaseko C, Nishiwaki K, et al. Discontinuation of dasatinib after deep molecular response for over 2 years in patients with chronic myelogenous leukemia and the unique profiles of lymphocyte subsets for successful discontinuation: a prospective, multicenter Japanese Trial (D-STOP Trial). Blood 2016 ; 128 : 791. [Google Scholar]
  41. Rea D, Dulphy N, Henry G, et al. Low natural killer (NK) cell counts and functionality are associated with molecular relapse after Imatinib discontinuation in patients (pts) with chronic phase (CP)-chronic myeloid leukemia (CML) with undetectable BCR-ABL transcripts for at least 2 years: Preliminary results from immunostim. On behalf of STIM investigators. Blood 2013 ; 122 : 856. [Google Scholar]
  42. Yoshida C, Iriyama N, Najima Y, et al. Association of peripheral regulatory T cells with achievement of deep molecular response in newly diagnosed chronic phase chronic myeloid leukemia treated with Dasatinib: the final results of D-First study. Blood 2016 ; 128 : 1916. [Google Scholar]
  43. Vey N, Bourrhis JH, Boissel N, et al. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood 2012; 120 : 4317–4323. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.